Global Pharmaceutical One-Material Blisters (OMB) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Pharmaceutical One-Material Blisters (OMB) market size was valued at US$ 484 million in 2025 and is forecast to a readjusted size of US$ 848 million by 2032 with a CAGR of 8.3% during review period.
Pharmaceutical One-Material Blisters (OMB) are unit-dose pharmaceutical packaging systems in which the blister-forming web and compatible lidding material are primarily made from the same polymer or are designed to enter the same material recycling stream. These blisters are mainly used for tablets, hard capsules, softgel capsules, lozenges, and other solid dosage forms, with cavities typically produced by thermoforming and sealed using push-through, peelable, or peel-push lidding materials. Commercial OMB structures are primarily based on PET, PP, PE, and, for higher-barrier applications, COC. In addition to improving recyclability and reducing dependence on conventional multi-material structures such as PVC–aluminum and cold-form aluminum blisters, pharmaceutical OMB solutions must meet strict requirements for moisture and oxygen barrier performance, seal integrity, drug compatibility, mechanical strength, machinability, patient accessibility, shelf-life protection, and regulatory compliance.
Key Findings
Global shipment volume reached approximately 36,154 MT in 2025
Average global selling price reached US$13 per kg in 2025
PET remains the broadest commercially available material platform
Tablets and hard capsules dominate pharmaceutical blister demand
Europe leads regulatory driven qualification and early commercialization
Supplier partnerships remain central to complete system commercialization
Market Trends
The market is shifting from conventional PVC–aluminum and multilayer barrier structures toward PET, PP and other polymer systems engineered for a single recycling stream. Product development is increasingly focused on transparent polymer lidding, improved push-through performance, wider forming and sealing windows, uniform residual wall thickness after thermoforming and compatibility with existing high-speed packaging equipment. PET has developed the broadest commercial partnership network: Huhtamaki’s mono-PET Push Tab lidding is paired with Klöckner Pentaplast’s kpNext R1 forming web, while PAXXUS supplies an alternative all-polyester pharmaceutical lid for the same forming-film platform. PP is gaining strategic importance because its moisture barrier is inherent to the polymer and can be retained across the thermoformed cavity wall; SÜDPACK, Liveo Research and TekniPlex have each developed PP or PP-stream-compatible systems. PE remains a more concentrated route represented by Amcor’s AmSky family, while COC supports medium-to-high barrier applications. The long-term direction is toward validated total-pack systems, third-party recyclability certification, lower material weight, aluminum and PVC reduction, mass-balance or recycled-content options and closer collaboration among resin producers, film converters, lidding suppliers, machinery companies and pharmaceutical customers.
Market Dynamics
Drivers
Sustainability commitments by pharmaceutical companies and evolving packaging policy are the principal market drivers. Regulation (EU) 2025/40 introduces lifecycle requirements covering packaging sustainability, minimization, labelling and waste management, creating a strong design signal for recyclable packaging even where pharmaceutical immediate packaging receives differentiated treatment to protect medicine quality and security of supply. At the customer level, OMB allows drug owners to reduce PVC and aluminum consumption, improve packaging carbon profiles and demonstrate progress toward circular-packaging objectives. Adoption is also supported by solutions that can run on existing blister lines without significant tooling changes or speed reductions, reducing the capital required for qualification. The commercialization of complete bottom-web and lidding combinations further lowers technical risk, while successful deployment in branded OTC products demonstrates that mono-material systems can move beyond laboratory trials into large-scale pharmaceutical use.
Restraints
The principal restraint is the technical and regulatory burden associated with replacing a validated primary pharmaceutical package. Standard PET structures generally provide lower moisture protection than PP, COC, PVdC-coated films or cold-form aluminum, limiting immediate conversion for highly hygroscopic drugs. Higher barrier performance can require specialty polymers, barrier layers or modified sealing systems, increasing material cost and complicating recycling claims. Each packaging change may require drug–package compatibility testing, seal-integrity verification, transportation testing, accelerated and long-term stability studies, equipment trials and regulatory documentation. India’s Drugs Rules require pharmaceutical packaging materials to comply with defined specifications and to be compatible with the drugs they contain, while China’s NMPA associated-review framework requires drug-packaging-material information and relevant changes to be maintained and evaluated with the finished medicine. Long validation cycles, conservative risk management and the possibility of requalification across multiple countries therefore slow conversion of established products.
Opportunities
The most attractive opportunity is the development of higher-barrier PP and COC systems capable of replacing selected PVC–PVdC, PVC–PCTFE and cold-form aluminum applications while remaining compatible with conventional form-fill-seal equipment. Additional opportunities include transparent aluminum-free packs, child-resistant and senior-friendly opening structures, thinner forming webs, printable polymer lids and systems incorporating chemically recycled or mass-balance resin. Export-oriented pharmaceutical manufacturers in India and China represent an important qualification pool because packaging for European and North American markets is increasingly assessed against sustainability and material-efficiency criteria. OTC medicines, generic tablets, vitamins and dietary supplements offer earlier conversion potential because many products have moderate barrier requirements and faster packaging-development cycles. Japan also presents an emerging development opportunity: KANAe has introduced a development-stage polyolefin PTP system evaluated for the PP recycling stream and designed for use on an existing packaging machine, indicating scope for localized material-and-machinery co-development.
Challenges
Manufacturers must balance recyclability with pharmaceutical safety, shelf-life protection and patient usability. A package described as one-material may still contain inks, coatings, sealants or functional layers that affect its acceptance in a specific recycling system. Collection and sorting infrastructure also varies significantly by country, meaning that technical recyclability does not automatically result in recycling at scale. Thermoforming redistributes film thickness, so barrier performance at the thinnest cavity areas must remain consistent across production speeds, tooling geometries and material batches. Lidding films must deliver reliable sealing while maintaining controlled push-through or peel forces, print quality and resistance to transport damage. Commercial risks include resin-price volatility, low early-stage production volumes, extended customer testing, uncertain pharmaceutical change timelines and the possibility that existing PVC or aluminum structures remain economically preferable for high-barrier products. Suppliers therefore need robust application laboratories, machine-testing capabilities, pharmaceutical quality systems and long-term technical support rather than relying solely on an environmental value proposition.
Industry Chain Analysis
The upstream industry comprises pharmaceutical-grade PET, PP, PE and COC resins, functional additives, heat-seal materials, barrier technologies, printing inks, coating chemicals and extrusion or thermoforming equipment. Midstream companies manufacture rigid forming webs, flexible or semi-rigid lidding films and complete matched blister systems through extrusion, coextrusion, coating, scoring, printing and slitting. Additional value is created through barrier testing, residual-wall-thickness analysis, sealing-window optimization, machine trials, stability support, recyclability assessment and regulatory documentation. Downstream customers include branded pharmaceutical companies, generic-drug manufacturers, CDMOs, contract packagers and nutraceutical producers. Resin suppliers and blister machinery manufacturers are important enabling participants but belong to different revenue pools from finished OMB film and complete-system suppliers. The highest-value capabilities are proprietary material formulation, validated forming-and-lidding combinations, cleanroom manufacturing, consistency between production batches and the ability to support pharmaceutical customers through qualification and post-approval packaging changes.
Segment Insights
PET Material is expected to remain the largest segment over the near term because it has the broadest base of commercially available forming webs and lidding materials. Klöckner Pentaplast supplies mono-PET bottom web, Huhtamaki and PAXXUS provide complementary PET lidding solutions, and Liveo Research, TekniPlex and Hysum Flexibles offer additional PET-based products or complete systems. The platform benefits from optical clarity, thermoformability, established material identification and the availability of push-through and peelable lid formats. PP Material is positioned as the key higher-growth platform because it offers stronger inherent moisture resistance and supports complete forming-and-lidding systems from SÜDPACK, Liveo Research and TekniPlex. The report’s Others segment should cover PE and COC rather than treating them as undefined residual products: PE is represented by recycle-ready thermoformed systems such as AmSky, while COC targets medium-to-high moisture-barrier applications and commands a higher material cost. This three-part segmentation—PET Material, PP Material and Others—therefore remains practical and mutually exclusive for market measurement.
Downstream Market Opportunities
Tablets represent the largest addressable application because they are extensively packaged in push-through unit-dose formats and can be accommodated by standardized cavity geometries. Hard capsules form the second major application and require deeper cavities, stable thermoforming and reliable protection against moisture. The Others category covers softgel capsules, lozenges and other solid-dose products where cavity design, chemical compatibility or opening performance differs from standard tablets. Early adoption is most likely in OTC drugs, generic medicines and nutraceutical products with low-to-medium barrier requirements, while moisture-sensitive prescription drugs offer higher-value opportunities for advanced PP and COC structures after stability validation. CDMOs and contract packagers are strategically important because a qualified material platform can be applied across multiple customers, formulations and regional product launches.
Regional Insights
Europe is the leading market for product development, qualification and early commercialization, supported by a concentrated pharmaceutical-packaging industry and a regulatory direction that emphasizes packaging minimization, circularity and improved waste management. Germany, Switzerland, the United Kingdom and neighboring converting hubs host many of the current OMB technology and partnership leaders. India offers significant long-term potential through its large generic-drug and export-manufacturing base, but adoption remains sensitive to material cost, existing line performance and the documentation required for primary-packaging changes under CDSCO rules. Export-oriented manufacturers and newly approved products are likely to adopt first. China combines a broad pharmaceutical-packaging supply chain with increasing interest in recyclable materials, and Hysum Flexibles has established a local APET forming-web and lidding platform. However, NMPA associated review and change-management requirements make pharmaceutical validation, registration support and stable domestic supply decisive competitive factors.
Report Scope
This report is a detailed and comprehensive analysis for global Pharmaceutical One-Material Blisters (OMB) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pharmaceutical One-Material Blisters (OMB) market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global Pharmaceutical One-Material Blisters (OMB) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global Pharmaceutical One-Material Blisters (OMB) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global Pharmaceutical One-Material Blisters (OMB) market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pharmaceutical One-Material Blisters (OMB)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pharmaceutical One-Material Blisters (OMB) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include SÜDPACK, Huhtamaki, Klöckner Pentaplast, Amcor, Liveo Research, TekniPlex, Hysum Flexibles, PAXXUS, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Pharmaceutical One-Material Blisters (OMB) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
PET Material
PP Material
Others
Market segment by Opening Mechanism
Push-Through Blisters
Peelable Blisters
Other
Market segment by Forming-Web Thickness
Thin-Gauge: ≤249 μm
Standard-Gauge: 249–359 μm
Thick-Gauge: ≥359 μm
Market segment by Application
Tablets
Hard Capsules
Others
Major players covered
SÜDPACK
Huhtamaki
Klöckner Pentaplast
Amcor
Liveo Research
TekniPlex
Hysum Flexibles
PAXXUS
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Pharmaceutical One-Material Blisters (OMB) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pharmaceutical One-Material Blisters (OMB), with price, sales quantity, revenue, and global market share of Pharmaceutical One-Material Blisters (OMB) from 2021 to 2026.
Chapter 3, the Pharmaceutical One-Material Blisters (OMB) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pharmaceutical One-Material Blisters (OMB) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Pharmaceutical One-Material Blisters (OMB) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pharmaceutical One-Material Blisters (OMB).
Chapter 14 and 15, to describe Pharmaceutical One-Material Blisters (OMB) sales channel, distributors, customers, research findings and conclusion.